Authors: Takashi Kobayashi Tomonobu Koizumi Toshihide Agatsuma Masanori Yasuo Kenji Tsushima Keishi Kubo Seiichiro Eda Hiroshi Kuraishi Shigeru Koyama Tsutomu Hachiya Nariaki Ohura
Publish Date: 2012/01/26
Volume: 69, Issue: 5, Pages: 1241-1246
Abstract
There is as yet no optimal treatment regimen for patients with epidermal growth factor receptor EGFR gene wildtype nonsmallcell lung cancer NSCLC that has progressed despite cytotoxic chemotherapy This trial was performed to evaluate the efficacy and toxicity of erlotinib a tyrosine kinase inhibitor of EGFR in Japanese patients with EGFR wildtype tumorsPatients with stage III/IV or postoperative recurrence of NSCLC whose tumors have wildtype EGFR were eligible Erlotinib 150 mg/day was administered until disease progression or unacceptable toxicity occurred The primary end point was disease control rate DCRThirtyone patients 23 men and 8 women median age 71 years range 31–89 were enrolled between January 2008 and June 2011 Twentyone had adenocarcinoma nine had squamous cell carcinoma and one had large cell carcinoma Ten nine eight and four patients showed performance status 0 1 2 and 3 respectively Erlotinib was administered following the median 31 regimens of cytotoxic chemotherapies One patient achieved complete response four showed partial response and eight had stable disease Thus response rate was 172 and DCR was 448 Skin rash was the most common side effect 806 Two patients developed interstitial lung disease Nevertheless all of these events were reversible and there were no treatmentrelated deaths The median progressionfree survival and survival times were 21 and 77 months respectively
Keywords: